In the breast cancer microenvironment, GPR132 inhibitors interfere with the lactate-GPR132-peroxisome proliferator–activated receptor γ axis and encourage tumor-associated macrophages to the M1-phenotype transformation (12). Here, GPR132 is linked to neoplasm.